Search clinical trials for: INCB059872

Total 6 results

Incyte Corporation

Terminated

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

Sickle Cell Disease

United States
Incyte Corporation

Terminated

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

Relapsed Ewing Sarcoma

United States, Spain, United Kingdom, Italy
Tianjin Medical University Second Hospital

Recruiting

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Solid Tumor | FGF Receptor Gene Mutation | FGF Amplification | FGF Receptor Gene Family Rearrangement | FGF Receptor Gene Translocation

China
Polyphor Ltd.

Terminated

Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa (PRISM-MDR)

Pneumonia

Brazil, Korea, Republic of, Mexico, South Africa, United States, Estonia, France, Hungary, Greece, Croatia, Israel, Spain, Thailand
Incyte Corporation

Terminated

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Metastatic Cancer | Solid Tumors | Advanced Malignancies

United States, United Kingdom, Spain
Incyte Corporation

Terminated

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Solid Tumors and Hematologic Malignancy

United States, Netherlands, Belgium

3

Subscribe